AJOVY® Formally Included in China's National Reimbursement Drug List 2026

SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- On November 14, NeuroGen announced that it's in-licensed innovative drug AJOVY^® (fremanezumab injection) from TEVA has been successfully listed on China's National Reimbursement Drug List (NRDL) following the latest round of national price negotiations¹. Marking a breakthrough as the first CGRP inhibitor covered by national insurance, AJOVY^® achieved same-year NRDL inclusion after its initial approval in June—a milestone expected to dramatically improve patient access and relieve the long-term financial burden for patients in China living with migraine.

• AJOVY^® is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand²
• Among currently marketed anti-CGRP monoclonal antibodies, fremanezumab injection is the only subcutaneous therapy offering both monthly and quarterly dosing options³
• Supported by multiple pivotal clinical studies, fremanezumab injection has proven effective and safe in adult migraine prevention, serving as the sole CGRP mAb to evaluate efficacy through a standalone Phase III trial in Chinese patients^4,5,6,7

Sean Chen, Chief Executive Officer of NeuroGen Pharma, stated: "Fremanezumab Injection's inclusion in the NRDL within the same year of approval reflects strong policy support for clinically needed innovation. As a key in-licensed product accelerating our local delivery of global innovations, its enhanced accessibility will bring breakthrough clinical benefits and financial relief to migraine patients. NeuroGen is fully committed to securing a steady nationwide supply, bringing cutting-edge innovation to benefit more families faster."

Migraine is a common chronic neurological disease. Evidence suggests that approximately 100 million individuals in China live with migraine⁸, with a 9.3% annual prevalence rate among adults aged 18 to 65⁹. Characterized by a substantial disease burden and recurrent attacks, migraine persistently impacts patients' work productivity, social activities, and overall quality of life⁸. Reducing attack frequency and mitigating its impact on daily life are therefore crucial goals in adult migraine management⁹.

AJOVY^® in China:

• 2023- It was approved by the Guangdong Provincial Medical Products Administration, pioneering the "Hong Kong and Macao Medicine and Equipment Connect" policy in the Guangdong-Hong Kong-Macao Greater Bay Area;
• 2024- Fremanezumab met its primary and all secondary endpoints in a China Phase III study, demonstrating efficacy in the Chinese population¹³;
• April 2026- NeuroGen entered a strategic partnership with Teva, obtaining exclusive commercialization rights in China¹⁴;
• June 2026- It was approved by the NMPA for the preventive treatment of migraine in adults¹⁵;
• November 2026- It was formally included in the China NRDL¹.

CGRP-targeted monoclonal antibodies, representing a core novel mechanism in preventive migraine therapy, are explicitly recommended across multiple domestic and international landmark guidelines. Key endorsees include the Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update¹¹ the Chinese Guidelines for the Diagnosis and Treatment of Migraine⁹, the Chinese practice guidelines for diagnosis and treatment of migraine¹⁰ and the Chinese expert consensus on the diagnosis and treatment of medication overuse headache¹².

About AJOVY^® (Fremanezumab Injection)

AJOVY is an innovative migraine treatment developed by Teva Pharmaceuticals and it offers both monthly (225mg) and quarterly (675mg) subcutaneous dosing options¹⁶. Among currently marketed anti-CGRP monoclonal antibodies, AJOVY is the only therapy offering these two dosing regimens³. The quarterly dosing option significantly reduces injection frequency, helping patients adhere to treatment and sustain long-term control of migraine attacks. The efficacy and safety of AJOVY are supported by multiple clinical studies. A China Phase III study in adult migraine demonstrated a significant reduction in monthly migraine days with a favorable safety profile⁴.

It was first approved in adults by the U.S. Food and Drug Administration (FDA) in 2018³ and by the European Medicines Agency (EMA) in 2019³. In 2025, AJOVY was approved by the FDA for single-dose injection use in children and adolescents aged 6–17 years with episodic migraine weighing 45 kg or more, becoming the world's first and only CGRP antagonist approved for both pediatric episodic migraine prevention and adult migraine prevention³.

About NeuroGen

NeuroGen Pharma was established in 2024 when Mubadala Investment Company and C-Bridge Capital jointly carved out CNS and Allergy originator portfolios of UCB and its Zhuhai Manufacturing site in China.

Leveraging its end-to-end capabilities covering R&D, manufacturing, and commercialization, NeuroGen focuses on addressing unmet clinical needs in neurology and allergy, with synergistic expansions into pain management. The company is building a scalable, growth-oriented biopharmaceutical platform dedicated to transforming care for better patient outcomes.

Visit us at www.neurogen.com.cn to learn more.

SOURCE NeuroGen